![Ellen Cavaleri](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ellen Cavaleri
Investor Relations Contact chez LYRA THERAPEUTICS, INC.
Postes actifs de Ellen Cavaleri
Sociétés | Poste | Début | Fin |
---|---|---|---|
LYRA THERAPEUTICS, INC. | Investor Relations Contact | 01/01/2022 | - |
Public Communications Contact | 01/01/2022 | - |
Historique de carrière de Ellen Cavaleri
Anciens postes connus de Ellen Cavaleri
Sociétés | Poste | Début | Fin |
---|---|---|---|
KADMON HOLDINGS, INC. | Investor Relations Contact | - | - |
Formation de Ellen Cavaleri
Vanderbilt University | Undergraduate Degree |
New York University | Masters Business Admin |
Statistiques
Internationale
Etats-Unis | 5 |
Opérationnelle
Investor Relations Contact | 2 |
Public Communications Contact | 1 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
LYRA THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Kadmon Holdings, Inc.
![]() Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
- Bourse
- Insiders
- Ellen Cavaleri
- Expérience